Anti-obesity medication (naltrexone/bupropion) in obesity management: single-centre early experience
Background: Naltrexone/bupropion is a recently approved antiobesity medication in Malaysia. We aimed to determine the 12-week outcomes of naltrexone/bupropion as an antiobesity medication at our centre. Methods: This was a single-centre, prospective, pilot, observational study. All patients prescrib...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Penerbit Universiti Sains Malaysia
2025
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/121029/ http://psasir.upm.edu.my/id/eprint/121029/1/121029.pdf |
| _version_ | 1848868277043855360 |
|---|---|
| author | Tan, Siow Foon Mukhtar, Firdaus Ng, Ooi Chuan Mohd Yusof, Barakatun Nisak Muhammadun Basar, Nur Adilah Changrabose, Thanalactchumy Cheng, Xiang Jun Nor Hanipah, Zubaidah |
| author_facet | Tan, Siow Foon Mukhtar, Firdaus Ng, Ooi Chuan Mohd Yusof, Barakatun Nisak Muhammadun Basar, Nur Adilah Changrabose, Thanalactchumy Cheng, Xiang Jun Nor Hanipah, Zubaidah |
| author_sort | Tan, Siow Foon |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | Background: Naltrexone/bupropion is a recently approved antiobesity medication in Malaysia. We aimed to determine the 12-week outcomes of naltrexone/bupropion as an antiobesity medication at our centre. Methods: This was a single-centre, prospective, pilot, observational study. All patients prescribed naltrexone/bupropion at Metabolic and Obesity Clinic, Hospital Sultan Abdul Aziz Shah, Universiti Putra Malaysia, between July 2023 and January 2024 were identified. The collected data included demographics, comorbidities, baseline weight, and body mass index. At the 12-week follow-up, data on weight, body mass index, side effects, and anti-craving effects were documented. Data are presented as mean ± standard deviation (SD) for continuous variables and as count and frequency for categorical variables. Results: Eighteen patients were treated with naltrexone/bupropion during the study. The majority were female (n = 13, 72%) and Malay (n = 13, 72%), with a mean age of 45 years (SD = 10). The mean body mass index was 38 kg/m2 (SD = 8). Comorbidities included diabetes (n = 9, 50%), hypertension (n = 7, 39%), and dyslipidaemia (n = 11, 61%). Of the 14 patients (78%) who completed 12 weeks of follow-up, the mean weight loss was 2.11 kg (SD = 2.61, P = 0.01), and the percentage of total body weight loss was 2%. The main side effects were giddiness (50%), nausea (44%), and headaches (38%). Naltrexone/bupropion was effective in reducing cravings in 75% of the patients. 63% of patients experienced side effects, which slowed escalation. Conclusion: Our early experience with naltrexone/bupropion as an antiobesity medication suggests that it is effective in managing obesity with craving symptoms. A longer follow-up with a larger group of patients is necessary before a definitive conclusion can be made. |
| first_indexed | 2025-11-15T14:49:50Z |
| format | Article |
| id | upm-121029 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T14:49:50Z |
| publishDate | 2025 |
| publisher | Penerbit Universiti Sains Malaysia |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-1210292025-10-22T09:30:48Z http://psasir.upm.edu.my/id/eprint/121029/ Anti-obesity medication (naltrexone/bupropion) in obesity management: single-centre early experience Tan, Siow Foon Mukhtar, Firdaus Ng, Ooi Chuan Mohd Yusof, Barakatun Nisak Muhammadun Basar, Nur Adilah Changrabose, Thanalactchumy Cheng, Xiang Jun Nor Hanipah, Zubaidah Background: Naltrexone/bupropion is a recently approved antiobesity medication in Malaysia. We aimed to determine the 12-week outcomes of naltrexone/bupropion as an antiobesity medication at our centre. Methods: This was a single-centre, prospective, pilot, observational study. All patients prescribed naltrexone/bupropion at Metabolic and Obesity Clinic, Hospital Sultan Abdul Aziz Shah, Universiti Putra Malaysia, between July 2023 and January 2024 were identified. The collected data included demographics, comorbidities, baseline weight, and body mass index. At the 12-week follow-up, data on weight, body mass index, side effects, and anti-craving effects were documented. Data are presented as mean ± standard deviation (SD) for continuous variables and as count and frequency for categorical variables. Results: Eighteen patients were treated with naltrexone/bupropion during the study. The majority were female (n = 13, 72%) and Malay (n = 13, 72%), with a mean age of 45 years (SD = 10). The mean body mass index was 38 kg/m2 (SD = 8). Comorbidities included diabetes (n = 9, 50%), hypertension (n = 7, 39%), and dyslipidaemia (n = 11, 61%). Of the 14 patients (78%) who completed 12 weeks of follow-up, the mean weight loss was 2.11 kg (SD = 2.61, P = 0.01), and the percentage of total body weight loss was 2%. The main side effects were giddiness (50%), nausea (44%), and headaches (38%). Naltrexone/bupropion was effective in reducing cravings in 75% of the patients. 63% of patients experienced side effects, which slowed escalation. Conclusion: Our early experience with naltrexone/bupropion as an antiobesity medication suggests that it is effective in managing obesity with craving symptoms. A longer follow-up with a larger group of patients is necessary before a definitive conclusion can be made. Penerbit Universiti Sains Malaysia 2025 Article PeerReviewed text en cc_by_4 http://psasir.upm.edu.my/id/eprint/121029/1/121029.pdf Tan, Siow Foon and Mukhtar, Firdaus and Ng, Ooi Chuan and Mohd Yusof, Barakatun Nisak and Muhammadun Basar, Nur Adilah and Changrabose, Thanalactchumy and Cheng, Xiang Jun and Nor Hanipah, Zubaidah (2025) Anti-obesity medication (naltrexone/bupropion) in obesity management: single-centre early experience. Malaysian Journal of Medical Sciences, 32 (2). pp. 42-49. ISSN 1394-195X; eISSN: 2180-4303 http://www.mjms.usm.my/MJMS32022025/05-mjms-11-2024-879.pdf 10.21315/mjms-11-2024-879 |
| spellingShingle | Tan, Siow Foon Mukhtar, Firdaus Ng, Ooi Chuan Mohd Yusof, Barakatun Nisak Muhammadun Basar, Nur Adilah Changrabose, Thanalactchumy Cheng, Xiang Jun Nor Hanipah, Zubaidah Anti-obesity medication (naltrexone/bupropion) in obesity management: single-centre early experience |
| title | Anti-obesity medication (naltrexone/bupropion) in obesity management: single-centre early experience |
| title_full | Anti-obesity medication (naltrexone/bupropion) in obesity management: single-centre early experience |
| title_fullStr | Anti-obesity medication (naltrexone/bupropion) in obesity management: single-centre early experience |
| title_full_unstemmed | Anti-obesity medication (naltrexone/bupropion) in obesity management: single-centre early experience |
| title_short | Anti-obesity medication (naltrexone/bupropion) in obesity management: single-centre early experience |
| title_sort | anti-obesity medication (naltrexone/bupropion) in obesity management: single-centre early experience |
| url | http://psasir.upm.edu.my/id/eprint/121029/ http://psasir.upm.edu.my/id/eprint/121029/ http://psasir.upm.edu.my/id/eprint/121029/ http://psasir.upm.edu.my/id/eprint/121029/1/121029.pdf |